CT-G32, also coded SCO-940, is an investigational peptide that its developers, Celltrion and SCOHIA PHARMA, describe as acting on four hormone pathways: GLP-1, GIP, glucagon and amylin. On November 4, 2026 they reported that in diet-induced obese rats it caused numerically greater weight loss than retatrutide at the same molar dose. No figures, statistics, structure or human data have been released.
Ask PeptideBlog about any peptide
Research snapshot
| Category | Current information |
|---|---|
| Peptide category | Investigational multi-receptor agonist (design intent) |
| Primary research interest | Obesity and related metabolic disease |
| Highest available evidence | Tier 3 (animal) as company-reported statements only; not peer reviewed; no numbers |
| Human research available | No |
| Development status | Preclinical; IND to FDA targeted by February 2027 (company target) |
| Regulatory status | Not approved anywhere. No registered trial found on ClinicalTrials.gov, Nov 6, 2026 |
Technical identity
| Technical property | Information |
|---|---|
| Primary name | SCO-940 (SCOHIA PHARMA) and CT-G32 (Celltrion), same candidate |
| Alternative names | None established. “CT632” appears only on a third-party site, not in either developer’s releases. Not CT-388 (enicepatide), an unrelated Roche drug whose code starts with the same letters |
| Peptide sequence, length | Not reliably established (not disclosed) |
| Molecular formula, weight | Not reliably established |
| CAS, PubChem, UNII, DrugBank | Not available |
| Chemical modifications | Not disclosed |
| Peptide class | Investigational multi-agonist; Celltrion calls it a “quadruple-action injectable” |
| Primary biological target | GLP-1, GIP, glucagon, amylin receptors (design intent) |
| Developer | SCOHIA PHARMA (Japan) discovery and preclinical; Celltrion (Korea) IND-enabling studies and onward |
| Development status | Preclinical |
What was announced, by whom and when
Celltrion and SCOHIA PHARMA presented the first CT-G32 / SCO-940 data at TIDES Europe, a peptide and oligonucleotide conference in Amsterdam, which ran November 3 to 5, 2026. SCOHIA published an English release on November 4 and Celltrion published a Korean-language release the same day. No presenter is named in either release, and no poster, abstract or paper is publicly available that we could find.
The background is short. The two companies began collaborating in 2024. SCOHIA announced the candidate on April 3, 2026, and said it led discovery and preclinical work while Celltrion is responsible for clinical development, regulatory work, manufacturing and commercialization. Celltrion’s own releases in February and May 2026 described the same program, targeting an IND in the first half of 2027.
Why it is called a quadruple agonist
An agonist switches a receptor on. Four hormone systems matter here, and each already has a drug built on it.
- GLP-1 and GIP are gut hormones released after eating. They affect appetite, stomach emptying and insulin release. Semaglutide acts on GLP-1; tirzepatide acts on both.
- Glucagon acts mainly on the liver and is linked to energy expenditure. Retatrutide adds glucagon activity to GLP-1 and GIP.
- Amylin is released with insulin and helps end meals and slow digestion. The differences between amylin drugs are laid out in amylin drugs compared.
CT-G32 is designed to act on all four. That is a design rationale, not a result. How strongly it acts on each receptor, and in what balance, has not been disclosed, and receptor balance likely matters more than receptor count. Celltrion describes the four-pathway combination as a world first “based on publicly disclosed development status,” which is a statement about the public record. Other preclinical multi-receptor programs exist. Selective amylin drugs such as eloralintide and glucagon-containing drugs such as survodutide and mazdutide are further along in human studies.
The rat experiment
The efficacy comparison used diet-induced obese (DIO) rats. Not mice: both developer releases say rats. At least one English-language outlet wrote “mouse,” which contradicts both.
SCOHIA’s English release says CT-G32 achieved “numerically greater weight loss at the same molar dose compared with retatrutide.” Three phrases in that sentence each need unpacking.
“Numerically greater” means the average for the CT-G32 group was a larger number. It does not say the difference was statistically significant, and Celltrion’s Korean release drops the qualifier and says only “greater.”
“Same molar dose” means the same number of molecules per unit of body weight. It is not the same weight in milligrams, because the two molecules differ in size. Neither company states an amount, so the match cannot be checked, and a molar match can still produce different exposure and tolerability. Celltrion’s Korean release says only “same dose.”
“Compared with retatrutide” refers to a rat comparison. There is no human comparison of any kind. Retatrutide has Phase 3 human data; CT-G32 has none.
The study duration, number of animals, sex, amounts, route and schedule were not disclosed.
Lean mass: share of weight lost versus amount of lean tissue lost
Both releases say a relatively smaller proportion of the weight lost was lean body mass. This is easy to misread in two ways.
First, a share is not an amount. If one group loses much more total weight, a smaller share of it can still be lean tissue while the absolute lean loss is equal or even larger. Only group-level numbers can settle that, and none were released.
Second, lean body mass is everything that is not fat: skeletal muscle, organs, water and other tissue, depending on how it is measured. Celltrion’s Korean release says the lean category includes muscle and skeletal components. SCOHIA’s does not break it down. Neither release names the measurement method. A smaller lean share in rats does not show protected muscle, strength or function, and nothing here supports a claim of proven muscle protection in people. For background on muscle loss with GLP-1 drugs in general, see GLP-1 drugs and muscle loss. Celltrion’s May 2026 release used stronger wording (“preservation of lean body mass, including muscle”) for earlier studies; the November data are described more cautiously.
The insulin statement
SCOHIA says CT-G32 “improved hyperinsulinemia associated with obesity” in the rats; Celltrion says it lowered excessive blood insulin. No insulin values, glucose, insulin sensitivity or food-intake data were given. Lower insulin can follow from lower body weight alone.
Thirteen methods questions the releases do not answer
| # | Question | Why it matters | Disclosed? |
|---|---|---|---|
| 1 | Animals per group | Small groups make numerical gaps unreliable | No |
| 2 | Randomization | Prevents allocation bias | No |
| 3 | Dose (nmol/kg or mg/kg) | “Same molar dose” is meaningless without the amount | No |
| 4 | Duration and timepoint | Weight curves differ early versus late | No |
| 5 | Effect sizes (absolute and percent weight change per arm) | The core result | No |
| 6 | Confidence intervals | Show uncertainty around the difference | No |
| 7 | Statistical significance | “Numerically greater” suggests none was claimed | No |
| 8 | Fat mass and lean mass, absolute | Share alone cannot show lean preservation | No |
| 9 | Receptor potency at all four targets | Balance drives behavior | No (activity assessed, values not given) |
| 10 | Animal sex | Rodent responses differ by sex | No |
| 11 | Blinding | Reduces measurement bias | No |
| 12 | Pharmacokinetics (half-life, exposure) | Needed to judge exposure at equal molar dose | Only “prolonged exposure” in primates |
| 13 | Toxicity | Needed before any human study | Program started; no results |
Which toxicology numbers belong to a different study
Celltrion’s May 29, 2026 release says that under its toxicology program it “will assess the safety and toxicity profile of CT-G32 in 252 rats and 48 monkeys.” Those are planned counts for a safety program that supports dose selection for future trials. They are not the group sizes of the November efficacy experiment and cannot be used to estimate them. The same release says earlier studies showed superior weight reduction “at equivalent doses relative to a benchmark candidate previously under development,” without naming it. November is the first time retatrutide is named.
What the monkey data do and do not say
The developers say non-human primates showed prolonged systemic exposure and that this supports the potential for a once-weekly formulation. That is a formulation possibility. No half-life, exposure figure or primate species was released, and a primate exposure profile does not establish a human interval, dose or tolerability. Celltrion describes CT-G32 as an injectable in its February and May releases, but the route and schedule used in the rat and primate studies were not disclosed.
What dosage information circulates?
Figures in this section summarize amounts and schedules reported in published research or circulating online. Their inclusion documents what is reported and does not establish that a regimen is verified, safe, effective, or appropriate.
No established or reliably sourced dosing information was identified.
| Reported use or research objective | Route reported | Amount reported | Frequency reported | Reported duration | Evidence or source category |
|---|---|---|---|---|---|
| Weight loss versus retatrutide, obese rats | Not disclosed | “Same molar dose,” no amount | Not consistently reported | Not consistently reported | Patent or developer documentation (company release, no data) |
| Lean mass and insulin, obese rats | Not disclosed | Not disclosed | Not consistently reported | Not consistently reported | Patent or developer documentation (company release, no data) |
| Pharmacokinetics, non-human primates | Not disclosed | Not disclosed | “Once-weekly potential” only | Not consistently reported | Patent or developer documentation (company release, no data) |
| Human use | None | None | None | None | No human research exists |
No figure appears across multiple sites with an identifiable origin, and any percentage or amount quoted online for CT-G32 has no source in the primary record. No animal amount should be converted into a human amount. For contrast, the amounts studied for retatrutide are covered in retatrutide dosage.
Timeline: targets versus milestones
| Date | Item | Type |
|---|---|---|
| 2024 | Collaboration begins | Reported by the companies |
| Feb 24, 2026 | Celltrion outlines CT-G32 as a quadruple-action injectable; IND 1H 2027 | Company release |
| Apr 3, 2026 | SCOHIA announces SCO-940 / CT-G32 | Company release |
| May 29, 2026 | Celltrion announces start of primate toxicology studies | Company release |
| Nov 3 to 5, 2026 | First preclinical data presented, Amsterdam | Conference |
| By Feb 2027 | IND submission to FDA | Target, not a milestone |
| Q2 2027 | First patient dosing, “if regulatory review proceeds smoothly” (Celltrion) | Target, not a milestone |
How to evaluate what comes next. An IND submission starts an FDA review; it is not approval, and the agency’s response period must pass before a US trial can begin. The first hard evidence of human development would be a ClinicalTrials.gov entry (an NCT number, phase, arms, enrollment and primary endpoint). As of November 6, 2026 the registry returned no CT-G32 or SCO-940 study and no Celltrion obesity study.
About CT632
A website at CT632.com circulates the code “CT632.” Neither the SCOHIA nor the Celltrion releases use that code; the verified development codes are CT-G32 and SCO-940. We treat the site as independent third-party commentary, not as a verified drug identifier, and do not link it. No judgment is made about the site itself.
Evidence-status table
| Item | Company assertion | Directly disclosed measurement | Unknown |
|---|---|---|---|
| Four-receptor activity | Yes | No values | Potency, balance |
| Greater weight loss than retatrutide (rats) | Yes, “numerically” | None | Size, N, duration, statistics |
| Smaller lean share of weight lost | Yes | None | Absolute lean and fat, method |
| Lower insulin | Yes | None | Values, glucose |
| Prolonged primate exposure | Yes | None | Half-life, species |
| Once-weekly feasibility | “Potential” | None | Human interval |
| Human efficacy, safety, dose | None | None | Everything |
Frequently asked questions
What is CT-G32?
An investigational peptide designed to act on GLP-1, GIP, glucagon and amylin receptors. SCOHIA calls it SCO-940.
Did it beat retatrutide?
In one rat comparison it showed numerically greater weight loss at the same molar dose, according to its developers. No figures or statistics were released and nothing has been compared in people.
What does “same molar dose” mean?
The same number of molecules, not the same weight. No amount was disclosed.
Does “numerically greater” mean significant?
No. It means a larger average, with no significance claim.
Does it protect muscle?
Not shown. A smaller lean share of weight lost in rats is not proven muscle protection.
Do the 252 rats and 48 monkeys belong to the efficacy study?
No. They are planned counts for a toxicology program announced in May.
Is it a once-weekly drug?
Not established. Primate exposure suggests it may be possible.
What dosage has been studied or is reported?
No established or reliably sourced dosing information was identified.
When could human trials start?
Celltrion targets an IND by February 2027 and first dosing in Q2 2027 if review goes smoothly. Those are targets.
Is CT632 the same as CT-G32?
The developers use CT-G32 and SCO-940. CT632 is not in their releases.
Bottom line
CT-G32 is interesting because it is the first disclosed attempt to add amylin to a retatrutide-style core in one molecule, and because the developers report a lean-mass and insulin signal in rats. The evidence is two company releases: no numbers, no statistics, no structure, no human data. The dosage information that is genuinely published is none. Everything else, including weekly dosing, muscle protection and superiority, is a hypothesis the next disclosures must test. Status: preclinical, IND targeted by February 2027. For another preclinical multi-receptor candidate, see the ASC37 audit.
More in the obesity peptides hub, or compare peptides side by side.
Related reading
- A plain-English explainer on how a fourth hormone pathway differs from three: CT-G32 vs retatrutide, what the early data show.
- A separate research article that reviews the same rat announcement beside retatrutide: CT-G32 (SCO-940) vs retatrutide, the four-receptor rat study.
Sources
| Source | Organization | Date | Category |
|---|---|---|---|
| First Research Results for SCO-940/CT-G32 at TIDES Europe 2026 | SCOHIA PHARMA | 2026-11-04 | Developer release |
| CT-G32/SCO-940 preclinical results (Korean) | Celltrion | 2026-11-04 | Developer release |
| Generation of Novel Quadruple Agonist SCO-940/CT-G32 | SCOHIA PHARMA | 2026-04-03 | Developer release |
| SCOHIA release index | SCOHIA PHARMA | read 2026-11-06 | Developer index |
| Celltrion obesity strategy release | Celltrion | 2026-02-24 | Developer release |
| Celltrion primate toxicology release | Celltrion | 2026-05-29 | Developer release |
| ClinicalTrials.gov search | NIH/NLM | searched 2026-11-06 | Government registry |
| Korea Herald coverage and Korea Biomedical Review | Press | 2026-11 | News |
CT-G32 is the only four-receptor candidate in the group. The triple agonist field beyond retatrutide explains how the three-receptor programs differ and how much evidence each has.